|
Subject: A retrospective, cross-sectional, observational survey study to understand the role of FDC of 1.0% Brinzolamide/0.5% Timolol eye drops in primary open angle glaucoma or ocular hypertension
Glaucoma is the leading cause of irreversible blindness in the world. The number of POAG cases in adult population (40–80 years old) estimated to be 79.76 million in 2040. Medical therapy for glaucoma is considered a mainstay of treatment. A great number of patients with primary open-angle glaucoma require combination therapy to efficiently compensate the IOP and prevent further development of glaucoma. There are several potential benefits of fixed combination medications compared with using the individual components separately. These include a reduction in the total number of drops and preservative instilled per day, cost savings, improved tolerability and compliance
This retrospective study aims to understand the role of FDC of 1.0% Brinzolamide/0.5% Timolol eye drops in primary open angle glaucoma or ocular hypertension
We invite you to participate in this data collection activity. All you need to do is to report on a standard form your experience with Brinzolamide and Timolo FDC eyedrops in management of glaucoma, in the normal course of your practice. If you agree to participate, you will need to fill data collection forms (which we call DCF).
We trust you and we are partners in promoting safe effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}